Adocia SA (LON:0QAI)

Market Cap	59.41M
Revenue (ttm)	10.03M
Net Income (ttm)	-7.71M
Shares Out	n/a
EPS (ttm)	-0.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5
Average Volume	118
Open	3.810
Previous Close	3.800
Day's Range	3.810 - 3.810
52-Week Range	3.150 - 10.900
Beta	0.97
RSI	48.83
Earnings Date	Sep 25, 2025

About Adocia

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company’s clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and ra...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2005
• Employees: 75
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QAI

Financial Performance

In 2024, Adocia's revenue was 12.12 million, an increase of 100.43% compared to the previous year's 6.05 million. Losses were -9.32 million, -55.95% less than in 2023.

Financial numbers in EUR